HAA方案治疗急性髓细胞白血病临床观察

Homoharringtonine,Cytarabine and Aclarubicin(HAA) Combination Chemotherapy for Acute Myeloid Leukemia(AML)

目的：观察ＨＡＡ方案治疗急性髓细胞白血病化疗效果。方法：初治急性髓细胞白血病１６例，应用ＨＡＡ方案诱导化疗。给药方法：高三尖杉酯碱（ＨＨＴ）３～４ｍｇ／日，静脉滴注（ｉｖ），连用７天；阿糖胞苷（Ａｒａ－Ｃ）１５０ｍｇ／ｍ２／日，ｉｖ，连用７天；阿克拉霉素（ＡＣＲ）４０ｍｇ／ｍ２／日，静脉注射，第１～３天，两疗程间休息２～３周。结果：完全缓解（ＣＲ）１４例，ＣＲ率８７．５％，１６例中１２例（７５％）１疗程即达ＣＲ。结论：ＨＡＡ方案是治疗急性髓细胞白血病的一种有效方案，该方案毒副作用可以耐受。ＨＴＴ和ＡＣＲ之间可能有协同作用。

Objective:To evaluate the efficacy of HAA regimen in acute myeloid leukemia(AML).Methods:Sixteen previously untreated patients with AML were treated with HAA regimen:homoharringtonine 3～4mg/d1 for 7 days,Ara C 150mg/m 2,d1 for 7 days,Aclarubicin 40mg/m 2,d1 for 3 days.Results:Of the 16 patients,14(87.5%) achieved complete remission (CR).Twelve/16(70%) patients achiveved CR with one cycle of treatment.It seems that HHT and ACR might be synergistic in the treatment of AML.The toxicities were well tolerated.Conclusion:HAA regimen is effective in the treatment of acute myeloid leukemia.